Susan Winckler
Chief Risk Management Officer
Leavitt Partners
As President of Leavitt Partners Consulting, a national health care consulting firm, and Chief Risk Management Officer for the Leavitt Partners family of businesses, Ms. Winckler advises corporate executives on policy and business matters, such as Medicare/Medicaid, FDA practices and alternative payment models. As CEO of the Food & Drug Law Institute from 2009 - 2014, she provided attorneys, regulators, industry leaders and consumers with journals, meetings and a neutral forum for
addressing domestic and global issues.
As FDA Chief of Staff from 2007-2009, Ms. Winckler managed the Commissioner’s office; served as his/her senior staff adviser; analyzed policies; and represented FDA before myriad government and external stakeholders. She simultaneously led FDA’s Offices of Legislation, External Relations, Public Affairs and Executive Secretariat.
As APhA Vice President Policy/Communications and Staff Counsel, Ms. Winckler served as the association’s lead
spokesperson and senior liaison to Congress, the executive branch, state associations and allied groups. Over the prior 9 years, she held several policy and practice-related jobs. Ms. Winckler earned a B.S. from the University of Iowa College of Pharmacy and her J.D. magna cum laude from Georgetown University Law Center. She is an APhA Fellow.
Recent Events and Presentations
Speeding Cures for Patients: How Congress Can Update the Prescription Drug User Fee Act to Spur Biopharmaceutical Innovation
For more than two decades, the Prescription Drug User Fee Act (PDUFA) has underpinned America’s leadership in biopharmaceutical innovation. Join ITIF for a discussion with policy experts, industry leaders, and patient advocates to discuss why a timely reauthorization of PDUFA is critical to the future of medical innovation.
